U.S. Markets closed

Evoke Pharma, Inc. (EVOK)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.1200-0.0200 (-1.75%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.1400
Open1.1600
Bid1.1000 x 1000
Ask1.1500 x 1400
Day's Range1.0800 - 1.1600
52 Week Range1.0600 - 6.0630
Volume110,806
Avg. Volume274,214
Market Cap36.257M
Beta (5Y Monthly)1.06
PE Ratio (TTM)N/A
EPS (TTM)-0.5140
Earnings DateAug 04, 2021 - Aug 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.00
  • Evoke Pharma Launches Gimoti® Patient and Physician Experience Program
    GlobeNewswire

    Evoke Pharma Launches Gimoti® Patient and Physician Experience Program

    Program intends to expand awareness and trial of GIMOTI among non-prescribing healthcare providersSOLANA BEACH, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the start of additional marketing initiatives focusing on the launch of a patient and physician experience program for GIMOTI, the Company’s nasal spray product for the relief of symptoms in acute and r

  • Evoke Pharma, EVERSANA and The International Foundation for Gastrointestinal Disorders Announce Membership into IFFGD’s Industry Council
    GlobeNewswire

    Evoke Pharma, EVERSANA and The International Foundation for Gastrointestinal Disorders Announce Membership into IFFGD’s Industry Council

    Extends commitment toward supporting patients experiencing Diabetic Gastroparesis through focused collaborations and Sponsorship of the 30th Anniversary Digestive Health Virtual WalkSOLANA BEACH, Calif., CHICAGO, and MOUNT PLEASANT, S.C., June 29, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, EVERSANA™, a leading provider of global commercial services to the life science industry, and The I

  • Evoke Pharma and EVERSANA Announce Positive Findings from Second GIMOTI® Market Research Study
    GlobeNewswire

    Evoke Pharma and EVERSANA Announce Positive Findings from Second GIMOTI® Market Research Study

    Results demonstrate continued increased awareness and intent to prescribe GIMOTISOLANA BEACH, Calif. and CHICAGO, June 15, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, and EVERSANA™, a leading provider of global commercial services to the life science industry, today announced positive findings from a second market research study conducted for GIMOTI® (metoclopramide) nasal spray. The stud